MedTrace Logo

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase 1 Clinical Tiral in Healthy Male Volunteers

NCT06736587 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 76

Last updated 2024-12-18

No results posted yet for this study

Summary

The safety and tolerability of single and multiple administration of DWP212525

Conditions

Interventions

DRUG

DWP212525 10mg

DWP212525 10mg

DRUG

DWP212525 30mg

DWP212525 30mg

DRUG

DWP212525 50mg

DWP212525 50mg

DRUG

DWP212525 100mg

DWP212525 100mg

DRUG

DWP212525 200mg

DWP212525 200mg

DRUG

DWP212525 400mg

DWP212525 400mg

DRUG

DWP212525 placebo

DWP212525 placebo

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-12-10
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06736587 on ClinicalTrials.gov